082800 — Vivozon Pharmaceutical Co Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapNeutral

Market Cap
KR₩331bn
Enterprise Value
KR₩360bn
Revenue
KR₩88bn

Annual balance sheet for Vivozon Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	—	—	—	—	—
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Cash
Cash and Equivalents
Short Term Investments
Cash and Short Term Investments	90,677	54,255	14,800	12,391	7,777
Net Total Accounts Receivable
Net Total Receivables	11,683	13,448	9,788	14,183	14,409
Total Inventory
Prepaid Expenses
Total Other Current Assets
Total Current Assets	122,404	96,333	47,562	45,138	44,407
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	25,228	32,807	33,968	25,521	31,814
Net Goodwill
Net Intangible Assets
Long Term Investments
Long Term Notes Receivable
Other Long Term Assets
Total Assets	248,159	194,471	187,074	173,647	184,449
Accounts Payable
Payable / Accrued
Accrued Expenses
Notes Payable / Short Term Debt
Current Portion of Long Term Debt / Capital Leases
Total Other Current Liabilities
Total Current Liabilities	111,570	89,023	77,817	64,779	72,211
Long Term Debt
Capital Lease Obligations
Total Long Term Debt
Total Debt
Deferred Income Tax
Minority Interest
Total Other Liabilities
Total Funded Status
Total Liabilities	140,356	109,350	81,237	69,580	78,022
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Treasury Stock
ESOP Debt Guarantee
Unrealized Gain / Loss
Other Equity
Total Equity	107,803	85,120	105,838	104,067	106,427
Total Liabilities & Shareholders' Equity	248,159	194,471	187,074	173,647	184,449
Total Common Shares Outstanding